Man Group
NKTR icon

Man Group’s Nektar Therapeutics NKTR Stock Holding History

Man Group’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-19,446
Closed -$1.4M – 2519
2026
Q1 		$1.4M Buy
+19,446
New +$1.11M ﹤0.01% 1719
2022
Q2 		– Sell
-1,344
Closed -$109K – 2300
2022
Q1 		$109K Buy
+1,344
New +$199K ﹤0.01% 2042
2021
Q2 		– Sell
-4,344
Closed -$1.3M – 2048
2021
Q1 		$1.3M Sell
4,344
-3,599
-45% -$1.12M 0.01% 1226
2020
Q4 		$2.02M Sell
7,943
-97
-1% -$25.1K 0.01% 1198
2020
Q3 		$2M Sell
8,040
-1,814
-18% -$571K 0.01% 1194
2020
Q2 		$3.42M Buy
+9,854
New +$3.07M 0.02% 841
2020
Q1 		– Sell
-3,873
Closed -$1.25M – 1789
2019
Q4 		$1.25M Sell
3,873
-9,391
-71% -$2.72M ﹤0.01% 1453
2019
Q3 		$3.62M Buy
13,264
+6,304
+91% +$2.31M 0.01% 1020
2019
Q2 		$3.71M Buy
6,960
+5,942
+584% +$2.98M 0.01% 1071
2019
Q1 		$513K Sell
1,018
-721
-41% -$427K ﹤0.01% 1727
2018
Q4 		$857K Sell
1,739
-12,475
-88% -$7.53M ﹤0.01% 1501
2018
Q3 		$13M Buy
14,214
+12,521
+740% +$10.7M 0.05% 497
2018
Q2 		$1.24M Sell
1,693
-440
-21% -$507K 0.01% 1540
2018
Q1 		$3.4M Buy
+2,133
New +$2.75M 0.02% 1053

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Man Group's NKTR Position: Q2 2026 in Review

Man Group sold out of Nektar Therapeutics (NKTR) in Q2 2026, closing a stake of 19,446 shares — an estimated $1.4M sold.

Man Group first reported a position in NKTR in Q1 2018 and held it in 14 quarters. The position peaked at $13M in Q3 2018. 240 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Man Group reported no remaining Nektar Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Man Group sold 19,446 Nektar Therapeutics shares in Q2 2026, an estimated $1.4M.
  • Man Group first reported a position in Nektar Therapeutics in Q1 2018 and held it in 14 quarters.
  • Man Group's Nektar Therapeutics position peaked at $13M in Q3 2018.
  • 240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.